"This grant will enable us to continue to advance our research in understanding the transmission of viral particles in order to prevent pandemic spread of virulent respiratory diseases, including influenza," said Frederick T. Koster, M.D., Associate Scientist, Infectious Diseases Program, Lovelace Respiratory Research Institute. "In order to screen large numbers of biological samples, we needed a technology partner that could provide high-resolution characterization of closely related viral strains, and could do so with appropriate sensitivity and high-throughput efficiency."
Respiratory diseases such as asthma, emphysema, influenza, and chronic bronchitis are on the increase worldwide. LRRI, one of the nation's largest independent research institutions and the only one focused solely on respiratory health, is committed to eradicating respiratory diseases through research aimed at understanding their causes and biological mechanisms, eliminating exposures to causal agents and developing more effective treatments.
Ibis' universal flu surveillance capabilities were described in a recent research study published in PLoS ONE in May 2007. In the study, Ibis' Dr. Sampath and colleagues report that they detected and correctly identified 92 mammalian and avian influenza isolates, including 29 avian H5N1 isolates. They also analyzed 656 human respiratory samples and showed correct, simultaneous identification of the viral species and subtypes with greater than 97 percent sensitivity and specificity.
ABOUT THE IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.
Ibis Biosciences, Inc., a wholly owned subsidiary of Isis
Pharmaceuticals, has developed the Ibis T5000(TM) Biosensor System for
rapid identification and characterization of infectious agents. The Ibis
T5000 is capable of identifying virtually all bacteria, viru
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved